PL3725803T3 - Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania - Google Patents

Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania

Info

Publication number: PL3725803T3
Authority: PL; Poland
Prior art keywords: binding molecules; complement factor; human complement; bind human; bind
Prior art date: 2013-05-23

Application number

PL20165165T

Other languages

English (en)

Inventor

Cornelis Erik Hack

Cafer YILDIZ

Louis Boon

Petrus Johannes Simons

Original Assignee

Broteio Pharma B.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-23

Filing date

2014-05-22

Publication date

2022-04-04

2014-05-22 Application filed by Broteio Pharma B.V. filed Critical Broteio Pharma B.V.

2022-04-04 Publication of PL3725803T3 publication Critical patent/PL3725803T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL20165165T 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania PL3725803T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP13168941		2013-05-23
EP14729463.1A EP2999714B1 (en)	2013-05-23	2014-05-22	Binding molecules that bind human complement factor c2 and uses thereof
EP20165165.0A EP3725803B1 (en)	2013-05-23	2014-05-22	Binding molecules that bind human complement factor c2b and uses thereof
PCT/NL2014/050327 WO2014189378A1 (en)	2013-05-23	2014-05-22	Binding molecules that bind human complement factor c2 and uses thereof

Publications (1)

Publication Number	Publication Date
PL3725803T3 true PL3725803T3 (pl)	2022-04-04

Family

ID=48485015

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL14729463T PL2999714T3 (pl)	2013-05-23	2014-05-22	Cząsteczki wiążące, które wiążą ludzki czynnik c2 dopełniacza oraz ich zastosowania
PL20165165T PL3725803T3 (pl)	2013-05-23	2014-05-22	Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL14729463T PL2999714T3 (pl)	2013-05-23	2014-05-22	Cząsteczki wiążące, które wiążą ludzki czynnik c2 dopełniacza oraz ich zastosowania

Country Status (14)

Country	Link
US (2)	US9944717B2 (pl)
EP (2)	EP2999714B1 (pl)
JP (3)	JP2016520313A (pl)
CN (1)	CN105492461B (pl)
AU (1)	AU2014269193C1 (pl)
CA (1)	CA2913318C (pl)
DK (2)	DK2999714T3 (pl)
ES (2)	ES2904709T3 (pl)
HU (2)	HUE049769T2 (pl)
LT (2)	LT2999714T (pl)
MX (1)	MX366046B (pl)
PL (2)	PL2999714T3 (pl)
PT (2)	PT3725803T (pl)
WO (1)	WO2014189378A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2912396T3 (es)	2012-11-02	2022-05-25	Bioverativ Usa Inc	Anticuerpos anti-C1s del complemento y uso de los mismos
US9944717B2 (en) *	2013-05-23	2018-04-17	Broteio Pharma B.V.	Binding molecules that bind human complement factor C2 and uses thereof
IL326479A (en) *	2016-10-12	2026-04-01	Bioverativ Usa Inc	Anti-c1s antibodies and methods of use thereof
PL3893924T3 (pl)	2018-12-13	2025-01-13	argenx BV	Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
GB2584105B (en)	2019-05-21	2023-08-02	Argenx Bvba	Methods of treating neuropathy
CN114502583A (zh) *	2019-08-12	2022-05-13	杰特创新股份有限公司	补体c2结合蛋白及其用途
US20250376539A1 (en) *	2022-01-29	2025-12-11	Kira Pharmaceuticals (Suzhou) Ltd.	Anti-c2 antibodies and uses thereof
MA71249A (fr)	2022-06-24	2025-04-30	Bioverativ Usa Inc.	Méthodes de traitement de maladies médiées par complément
GB202407051D0 (en)	2024-05-17	2024-07-03	argenx BV	Methods of treating osteoarthritis pain
WO2025257157A1 (en)	2024-06-10	2025-12-18	argenx BV	Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) *	2024-06-17	2025-12-26	CSL Innovation Pty Ltd	Anti-c2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US6998468B2 (en) *	2000-03-23	2006-02-14	Tanox, Inc.	Anti-C2/C2a inhibitors of complement activation
US9944717B2 (en) *	2013-05-23	2018-04-17	Broteio Pharma B.V.	Binding molecules that bind human complement factor C2 and uses thereof

2014
- 2014-05-22 US US14/892,850 patent/US9944717B2/en active Active
- 2014-05-22 PT PT201651650T patent/PT3725803T/pt unknown
- 2014-05-22 ES ES20165165T patent/ES2904709T3/es active Active
- 2014-05-22 DK DK14729463.1T patent/DK2999714T3/da active
- 2014-05-22 JP JP2016515304A patent/JP2016520313A/ja active Pending
- 2014-05-22 HU HUE14729463A patent/HUE049769T2/hu unknown
- 2014-05-22 DK DK20165165.0T patent/DK3725803T3/da active
- 2014-05-22 CA CA2913318A patent/CA2913318C/en active Active
- 2014-05-22 WO PCT/NL2014/050327 patent/WO2014189378A1/en not_active Ceased
- 2014-05-22 PT PT147294631T patent/PT2999714T/pt unknown
- 2014-05-22 HU HUE20165165A patent/HUE057858T2/hu unknown
- 2014-05-22 EP EP14729463.1A patent/EP2999714B1/en active Active
- 2014-05-22 PL PL14729463T patent/PL2999714T3/pl unknown
- 2014-05-22 PL PL20165165T patent/PL3725803T3/pl unknown
- 2014-05-22 EP EP20165165.0A patent/EP3725803B1/en active Active
- 2014-05-22 AU AU2014269193A patent/AU2014269193C1/en active Active
- 2014-05-22 LT LTEP14729463.1T patent/LT2999714T/lt unknown
- 2014-05-22 MX MX2015016120A patent/MX366046B/es active IP Right Grant
- 2014-05-22 CN CN201480042146.0A patent/CN105492461B/zh active Active
- 2014-05-22 LT LTEP20165165.0T patent/LT3725803T/lt unknown
- 2014-05-22 ES ES14729463T patent/ES2784616T3/es active Active
2018
- 2018-02-23 US US15/903,810 patent/US10717785B2/en active Active
2019
- 2019-08-13 JP JP2019148550A patent/JP7163254B2/ja active Active
2022
- 2022-10-19 JP JP2022167816A patent/JP7414929B2/ja active Active

Also Published As

Publication number	Publication date
ES2904709T3 (es)	2022-04-05
HUE049769T2 (hu)	2020-10-28
MX2015016120A (es)	2016-10-28
WO2014189378A1 (en)	2014-11-27
US20160108134A1 (en)	2016-04-21
LT2999714T (lt)	2020-07-10
ES2784616T3 (es)	2020-09-29
AU2014269193B2 (en)	2019-08-15
US10717785B2 (en)	2020-07-21
JP7414929B2 (ja)	2024-01-16
LT3725803T (lt)	2022-03-10
DK2999714T3 (da)	2020-06-02
CA2913318C (en)	2024-03-26
EP3725803A1 (en)	2020-10-21
CN105492461B (zh)	2019-11-26
JP2020007318A (ja)	2020-01-16
EP2999714A1 (en)	2016-03-30
JP2016520313A (ja)	2016-07-14
AU2014269193C1 (en)	2020-02-20
JP2023002684A (ja)	2023-01-10
DK3725803T3 (da)	2022-03-07
JP7163254B2 (ja)	2022-10-31
MX366046B (es)	2019-06-26
HK1223385A1 (zh)	2017-07-28
CA2913318A1 (en)	2014-11-27
CN105492461A (zh)	2016-04-13
US9944717B2 (en)	2018-04-17
EP3725803B1 (en)	2021-12-15
US20180319895A1 (en)	2018-11-08
EP2999714B1 (en)	2020-04-01
AU2014269193A1 (en)	2015-12-17
HUE057858T2 (hu)	2022-06-28
PL2999714T3 (pl)	2020-10-19
PT3725803T (pt)	2021-12-24
PT2999714T (pt)	2020-04-30

Publication	Publication Date	Title
IL276106A (en)	2020-08-31	Garp-binding proteins and their uses
ZA201505209B (en)	2019-07-31	Binding molecules for bcma and cd3
LT3725803T (lt)	2022-03-10	Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2b, ir jų panaudojimas
IL254223A (en)	2017-10-31	CD20 binding compounds and their uses
IL240045A0 (en)	2015-08-31	Antigen-binding molecules activate bi-specific t cells
SG11201505762XA (en)	2015-08-28	Il-11r binding proteins and uses thereof
ZA201803841B (en)	2019-04-24	Binding molecules specific for asct2 and uses thereof
ZA201506186B (en)	2016-11-30	Ligand binding molecules and uses thereof
ZA201500872B (en)	2016-06-29	Rspo3 binding agents and uses thereof
SI3072905T1 (sl)	2020-12-31	IL-17A-vezavno sredstvo in uporabe le-tega
IL237845A0 (en)	2015-05-31	New 17a–il binding molecules and their medical uses
GB201306588D0 (en)	2013-05-29	Peptides and Binding Partners Therefor
ZA201503962B (en)	2016-07-27	Fines binding process and binding composition thereof
ZA201603596B (en)	2020-11-25	Fabs-in-tandem immunoglobulin and uses thereof
HU4488U (en)	2015-01-28	Plaster-coated and edge-protected chipboard